Related Experiment Videos
Drug companies have a duty to continue treatment
1National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia.
BMJ (Clinical Research Ed.)
|March 22, 1997
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Targeting unique ligand binding domain structural features downregulates DKK1 in Y537S ESR1 mutant breast cancer cells.
Breast cancer research : BCR·2025
Targeting Unique Ligand Binding Domain Structural Features Downregulates DKK1 in Y537S ESR1 Mutant Breast Cancer Cells.
bioRxiv : the preprint server for biology·2024
Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study.
Clinical pharmacology and therapeutics·2015
Advances in the diagnosis and management of skin and soft tissue infections.
BMJ (Clinical research ed.)·2026
Navigating Therapeutic Frontiers: A Meta-review and Meta-analysis of COVID-19 Treatment Options.
Journal of research in pharmacy practice·2026
Population-level benefits of correctional medications for opioid use disorder.
Journal of substance use and addiction treatment·2026
Opioid-Sparing Sedation for Gastrostomy Tube Placement: A Retrospective Cohort Study Comparing Ketamine/Midazolam and Fentanyl/Midazolam.
Journal of vascular and interventional radiology : JVIR·2026
People who use drugs as frontline responders: Rethinking overdose response training through lived experience.
The International journal on drug policy·2026
Inhibition of PARP1-mediated parthanatos by rucaparib phosphate alleviates sepsis-induced acute lung injury.
International immunopharmacology·2026